{"nctId":"NCT02418845","briefTitle":"A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis","startDateStruct":{"date":"2015-05-28","type":"ACTUAL"},"conditions":["Bacterial Vaginosis"],"count":189,"armGroups":[{"label":"SYM-1219","type":"EXPERIMENTAL","interventionNames":["Drug: SYM-1219"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"SYM-1219","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Are premenopausal adult females or post menarchal adolescent girls ≥12 years of age in good general health\n* Have a clinical diagnosis of bacterial vaginosis, defined as having all of the following criteria:\n* Off-white (milky or gray), thin, homogeneous vaginal discharge\n* Vaginal pH ≥ 4.7\n* Presence of Clue cells of ≥ 20% of the total epithelial cells on microscopic examination of the vaginal saline wet mount\n* A positive 10% KOH Whiff test\n* Have a Gram stain slide Nugent Score ≥ 4 at the Baseline Visit (Day 1)\n\nExclusion Criteria:\n\n* Are pregnant, lactating, or planning to become pregnant during the study\n* Are menstruating or have vaginal bleeding at the Baseline Visit (Day 1)\n* Are suspected clinically (or confirmed diagnostically) of having alternative causes of vaginal symptoms including candidiasis, Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae or Herpes simplex\n* Have received antifungal or antimicrobial therapy (systemic or intravaginal) within 14 days prior to the Baseline Visit (Day 1)","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Outcome Responder Rate","description":"Determined by Normal vaginal discharge, negative 10% KOH Whiff test, \\& Clue cells less than 20%","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Outcome Responder Rate (Interim Visit Only)","description":"Determined by Normal vaginal discharge, negative 10% KOH Whiff test, \\& Clue cells less than 20%","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"14","spread":null}]},{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Gram Stain Slide Nugent Score","description":"A score of 0-3 will be considered normal; a score of 4 and above will be considered abnormal","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Therapeutic Outcome Responder Rate","description":"A Therapeutic Outcome Responder is defined as a Clinical Outcome Responder with a normal Nugent Score (between 0-3)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]},{"type":"SECONDARY","title":"Investigator's Clinical Assessment","description":"Investigator's opinion of the need for additional Bacterial Vaginosis (BV) treatment (Yes or No)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"38","spread":null}]},{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"16","spread":null}]},{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":125},"commonTop":["Vulvovaginal mycotic infection","Vulvovaginal candidiasis","Headache","Nausea","Diarrhoea"]}}}